XTORO 0.3 % — DIN 02452928
FINAFLOXACIN : 0.3 % · MERLION PHARMACEUTICALS GMBH · SUSPENSION · wholesale supply in Canada
Health Canada status: APPROVED
What is XTORO?
XTORO 0.3 % contains FINAFLOXACIN : 0.3 %. It is listed in the Health Canada Drug Product Database under DIN 02452928, held by MERLION PHARMACEUTICALS GMBH, supplied as SUSPENSION for OTIC administration. Health Canada currently lists it as approved, status dated 11-Mar-2019. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A). This DIN is not currently being marketed in Canada, so it is sourced to order where a compliant route exists rather than held in stock.
How is it supplied and stored?
Pack configuration, storage class and the handling constraints that drive cold-chain planning. One DIN can cover more than one pack size, and the pack — not the DIN — is what gets priced, shipped and invoiced.
| Strength on the label | 0.3 % |
|---|---|
| Dosage form | SUSPENSION |
| Route | OTIC |
Before an order line is unambiguous Nexara needs the strength, the pack size and the presentation.
Substance and classification
| Active substance | Antiinfectives |
|---|---|
| ATC code | S02AA |
| AHFS class | 52:04.04 |
| Biosimilar biologic | No |
Health Canada record and identifiers
The regulatory facts straight from the Drug Product Database, plus every identifier form Nexara accepts on a purchase order. A DIN written without its leading zeros is the commonest reason an order line fails to match.
| DIN (8-digit, as used in ordering) | 02452928 |
|---|---|
| DIN (unpadded, as printed on some documents) | 2452928 |
| Brand name | XTORO |
| Generic / active ingredient | FINAFLOXACIN : 0.3 % |
| Market authorization holder | MERLION PHARMACEUTICALS GMBH |
| Health Canada schedule | Prescription |
| ATC code | S02AA |
| ATC anatomical main group | S — Sensory organs |
| ATC therapeutic subgroup | S02AA |
| Current status | APPROVED |
| Status date | 11-Mar-2019 |
| Status source | Live Health Canada DPD sync |
Verify on the primary sources
What can be used instead?
Alternatives on every axis a buyer actually considers — the same molecule in another presentation, the same class, an adjacent class, or a fixed-dose combination. Every row is led by the marketed DIN count, because that is what can be bought this week.
2 · Same class — other molecules in ATC S02AA
| Molecule | Canadian brands | DINs | Marketed | Sourceable |
|---|---|---|---|---|
| Antiinfectives, Combinations | ANTIBIOTIC EAR DROPS · BURO-SOL OTIC SOLUTION · LIDOMYXIN · LIDOSPORIN EAR DROPS · +3 more | 7 | 1 | Yes |
| Gentamicin | GARAMYCIN OTIC DROPS 0.3% · GARATEC OTIC DPS 5MG/ML · PMS-GENTAMICIN OTIC DROPS 0.3% · SANDOZ GENTAMICIN | 4 | 0 | Not in Canada |
| Antiinfectives | XTORO | 1 | 0 | Not in Canada |
| Chloramphenicol | SOPAMYCETIN SOLN OTIQUE 5% | 1 | 0 | Not in Canada |
A molecule with zero marketed DINs cannot be sourced domestically, however many approvals it holds — if one of these sits on a formulary or in an older protocol, that is the line to check.
Not clinical advice. These tables describe what can be supplied in Canada, not what should be prescribed. Substitution within or across classes is a prescriber and pharmacist decision, and interchangeability is determined provincially.
How can I get it?
This product is approved by Health Canada but not yet marketed in Canada, so there is no Canadian supply to draw on today. Nexara can tell you whether it has been launched, and can look at supply from other markets where a Canadian pack is not required or where importation is permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address. Patients and unlicensed buyers are routed to a partner pharmacy.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Why is there no price on this page?
Nexara quotes a delivered Canadian price per order, against a verified licence. Foreign list prices are published on incompatible bases and are not a guide to what any buyer can obtain here, so this page shows which markets list the molecule and on what basis, and nothing more.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.